The PrESTs were coupled to phagocytable particles, processed as previously described (29, 30), and used to stimulate peripheral blood mononuclear cells (PBMCs) from natalizumab-treated persons with MS (pwMSs; n = 16) and age- and sex-matched healthy controls (HCs; n = 9) (cohort characteristics in table S2) in an interferon-γ (IFNγ)/interleukin-22 (IL-22)/IL-17A FluoroSpot assay. This evidence concerns the gene IL22 and myeloid sarcoma.